Table 3.
Effects of factors identified as affecting biglycan (BGN) on expression of other dermal extracellular matrix-related genes.
| Gene | CCL28 | N,N-Dimethylglycine | CXCL4 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| vs control (1.00) | p value | vs control (1.00) | p value | vs control (1.00) | p value | ||||
| COL1A1 | 0.72 ± 0.05 | ↓ | < 0.01 | 0.89 ± 0.05 | ↓ | < 0.10 | 0.93 ± 0.14 | – | 0.47 |
| COL1A2 | 0.79 ± 0.03 | ↓ | < 0.01 | 0.83 ± 0.08 | ↓ | < 0.05 | 0.98 ± 0.03 | – | 0.58 |
| COL3A1 | 0.81 ± 0.06 | ↓ | < 0.05 | 0.91 ± 0.09 | – | 0.20 | 0.82 ± 0.07 | ↓ | < 0.05 |
| COL5A1 | 0.68 ± 0.05 | ↓ | < 0.01 | 0.74 ± 0.04 | ↓ | < 0.01 | 1.01 ± 0.05 | – | 0.88 |
| COL6A1 | 0.94 ± 0.07 | – | 0.21 | 0.92 ± 0.03 | – | < 0.05 | 1.00 ± 0.04 | – | 0.85 |
| COL12A1 | 0.73 ± 0.05 | ↓ | < 0.01 | 0.86 ± 0.05 | ↓ | < 0.05 | 1.01 ± 0.12 | – | 0.91 |
| COL14A1 | 0.73 ± 0.04 | ↓ | < 0.01 | 0.92 ± 0.20 | – | 0.57 | 0.71 ± 0.02 | ↓ | < 0.01 |
| HAS1 | 0.38 ± 0.14 | ↓ | < 0.01 | 0.23 ± 0.11 | ↓ | < 0.01 | 1.53 ± 0.18 | ↑ | < 0.05 |
| HAS2 | 0.74 ± 0.05 | ↓ | < 0.01 | 1.05 ± 0.04 | – | 0.28 | 1.32 ± 0.11 | ↑ | < 0.05 |
| DCN | 0.70 ± 0.07 | ↓ | < 0.01 | 0.91 ± 0.07 | ↓ | < 0.10 | 0.85 ± 0.05 | ↓ | < 0.05 |
| BGN | 0.56 ± 0.05 | ↓ | < 0.01 | 0.76 ± 0.03 | ↓ | < 0.05 | 0.83 ± 0.04 | ↓ | < 0.10 |
| VCAN | 0.83 ± 0.07 | ↓ | < 0.05 | 0.89 ± 0.09 | – | 0.12 | 1.03 ± 0.03 | – | 0.32 |
| CHPF | 0.76 ± 0.05 | ↓ | < 0.01 | 0.84 ± 0.03 | ↓ | < 0.01 | 1.07 ± 0.02 | ↑ | < 0.05 |
| CHSY1 | 0.72 ± 0.05 | ↓ | < 0.001 | 0.91 ± 0.03 | ↓ | < 0.05 | 1.07 ± 0.05 | – | 0.10 |
| CHSY3 | 0.76 ± 0.04 | ↓ | < 0.01 | 0.93 ± 0.07 | – | 0.24 | 0.96 ± 0.08 | – | 0.50 |
| ELN | 0.71 ± 0.02 | ↓ | < 0.001 | 0.86 ± 0.09 | ↓ | < 0.10 | 1.09 ± 0.06 | – | 0.11 |
Values show the means of the relative gene expression amounts calculated by the ΔΔCt method (where Ct is the threshold cycle) normalized with glyceraldehyde 3-phosphate dehydrogenase as the housekeeping gene and the control sample ± standard errors (SEs). Statistical analyses were performed with two-sided independent t tests.
BGN byglycan, CCL28 C–C motif chemokine ligand 28, CHPF chondroitin polymerizing factor, CHSY1 chondroitin sulfate synthase 1, CHSY3 chondroitin sulfate synthase 3, COL1A1 collagen type I α 1 chain, COL1A2 collagen type I α 2 chain, COL3A1 collagen type III α 1 chain, COL5A1 collagen type V α 1 chain, COL6A1 collagen type VI α 1 chain, COL12A1 collagen type XII α 1 chain, COL14A1 collagen type XIV α 1 chain, CXCL4 C–X–C motif chemokine 4, DCN decorin, ELN elastin, HAS1 hyaluronan synthase 1, HAS2 hyaluronan synthase 2, VCAN versican.